
The current forms of immunotherapy, how T cell therapy works and what the future holds

Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

